Accelerate Diagnostics, Inc. announced preliminary unaudited revenue results for the year ended December 31, 2023. Preliminary revenue was approximately $12.1 million for the year, compared to $12.8 million in the prior year. While year-over-year revenues for consumable products increased by approximately 5%, overall annual revenue was down year-over-year due to a challenging capital sales environment in all sales regions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.15 USD | -1.71% |
|
-1.71% | -70.66% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-70.66% | 27.63M | |
+0.20% | 205B | |
+3.65% | 178B | |
+31.11% | 158B | |
+32.35% | 112B | |
+1.79% | 64.58B | |
+22.60% | 55.34B | |
-3.27% | 46.64B | |
-9.79% | 36.78B | |
-0.58% | 34.85B |
- Stock Market
- Equities
- AXDX Stock
- News Accelerate Diagnostics, Inc.
- Accelerate Diagnostics, Inc. Announces Preliminary Unaudited Revenue Results for the Year Ended December 31, 2023